Abstract
BackgroundMalignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to asbestos and results in a poor prognosis. Effective therapeutics as well as early diagnostics for the MPM are still lacking. To identify potential diagnostic biomarkers for MPM, we performed bioinformatics analysis of public database.MethodsUtilizing databases from Cancer Cell Line Encyclopedia (CCLE) and Gene Expression Omnibus (GEO), we identified several potential candidates that could act as MPM biomarkers. We carried out additional molecular analyses of these potential markers using MPM patient tissue samples via quantitative polymerase chain reaction.ResultsWe identified Lysyl oxidase (LOX), Lysyl oxidase homologs 1&2 (LOXL1& LOXL2) Zinc Finger Protein, FOG Family Member 2 (ZFPM2) as potential diagnostic biomarkers for MPM. In this study, we found that the LOX family and ZFPM2 showed comparable diagnostic ability to Fibulin-3 or mesothelin (MSLN) and would be better potential biomarkers than Sulfatase 1 (SULF1), Thrombospondin 2 (THBS2) and Cadherin 11 (CDH11).ConclusionsLOX family and ZPFM2 were identified as novel MPM diagnostic biomarkers which could strengthen MPM clinical diagnostic capabilities.
Highlights
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs
The soluble mesothelin-related protein (SMRP) has been detected in the serum of 84% of the MPM patients making it reasonably sensitive and suggesting its potential to act as an MPM diagnostic marker [11]
Gene expression patterns were comprehensively analyzed between 14 MPM cell lines and 32 lung adenocarcinoma cell lines using Gene Set Enrichment Analysis (GSEA)
Summary
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to asbestos and results in a poor prognosis. Effective therapeutics as well as early diagnostics for the MPM are still lacking. To identify potential diagnostic biomarkers for MPM, we performed bioinformatics analysis of public database. Malignant pleural mesothelioma (MPM) is a highly malignant tumor which occurs in the pleural mesothelial tissues covering the lung [1]. It is well known that MPM onset is usually due to asbestos exposure in an industrial environment [2]. Due to the prolonged latency of asbestos, asbestos mediated-MPM commonly occurs from 20 to 50 years following exposure. The SMRP has been detected in the serum of 84% of the MPM patients making it reasonably sensitive and suggesting its potential to act as an MPM diagnostic marker [11]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
